The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

9 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification of new SUMO activating enzyme 1 inhibitors using virtual screening and scaffold hopping.EBI
Riken
Identification of quinazolinyloxy biaryl urea as a new class of SUMO activating enzyme 1 inhibitors.EBI
Riken
Exploring a new frontier in cancer treatment: targeting the ubiquitin and ubiquitin-like activating enzymes.EBI
University of Toronto Mississauga
NAE modulators: A potential therapy for gastric carcinoma.EBI
Southwest Jiaotong University
Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.EBI
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.EBI
Temple University
Heteroaryl compounds useful as inhibitors of SUMO activating enzymeBDB
Millennium Pharmaceuticals
Molecular cloning and characterization of a new receptor for galanin.BDB
Merck Research Laboratories